Highly purified cannabidiol (CBD) in CDKL5 deficiency disorder (CDD): Open-label prospective study.
A new open-label study examining CBD for CDKL5 deficiency disorder treatment found 89% of patients continued therapy for 12 months. While retention rates suggest tolerability, efficacy data remains limited in this rare developmental epilepsy condition.
Cannabidiol in Developmental Epilepsy: Organoid-Guided Precision Medicine Across Critical Neurodevelopmental Windows
This review highlights cbd neurodevelopmental epilepsy precision medicine strategies using organoid models to guide treatment timing. It synthesizes evidence of CBD’s multiple mechanisms in developmental epilepsies. The research emphasizes the need for…
Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav
Jazz Pharmaceuticals is advancing pharmaceutical grade CBD research with new findings on Epidiolex and Xywav. This research helps establish evidence-based dosing protocols and safety profiles. Such data is critical for broader cannabinoid medicine…
Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav … – Investors
Jazz Pharmaceuticals continues pharmaceutical CBD research with new presentations on Epidiolex. These studies focus on expanding evidence-based cannabinoid medicine beyond approved epilepsy indications. Pharmaceutical CBD research informs off-label…
A Desperate North Texas Mom Turns to CBD to Stop Her Son’s Seizures
Pediatric epilepsy CBD treatment offers hope for children with refractory seizures. However, legal access to CBD remains complex across states, impacting families' care options. This article highlights the challenges and clinical perspectives on CBD use…
Fitch Affirms Jazz’s IDR at ‘BB’; Outlook Stable
Credit rating stability pharmaceutical cannabis is crucial for maintaining access to Epidiolex, the FDA-approved cannabidiol medication for pediatric epilepsy. Fitch Ratings affirmed Jazz Pharmaceuticals' credit rating at 'BB' with a stable outlook,…
Ameliorating Seizures in Dravet Syndrome: A Review of Newly Approved and Investigational Drugs, RNA and Gene-Based Therapies.
Dravet syndrome is a severe pediatric epilepsy with drug-resistant seizures. This review focuses on ameliorating seizures in Dravet syndrome using newly approved and investigational therapies. Cannabinoid and gene-based treatments show promise in…
Endocannabinoid System Research: Cannabinoids for Children
Cannabinoids for pediatric care have been studied in various medical conditions with evolving evidence. The strongest data supports use in specific epilepsy syndromes. Safety and efficacy findings in other pediatric conditions remain limited and variable.